Related Experiment Video

Updated: Apr 24, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

Vitronectin silencing inhibits hepatocellular carcinoma in vitro and in vivo

Wei Zhu1, Wenxue Li, Guangyu Yang

  • 1Department of Toxicology, Guangzhou Center for Disease Control & Prevention, Guangzhou, Guangdong 510080, PR China.

Future Oncology (London, England)
|September 3, 2014
PubMed
Abstract

Insights

Inhibiting vitronectin (VTN) significantly suppressed the malignant growth of hepatocellular carcinoma cells in vitro and in vivo. This suggests VTN inhibition is a promising therapeutic strategy for liver cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) is a major global health concern.
  • Vitronectin (VTN) is a protein implicated in tumor progression and metastasis.
  • Targeting VTN presents a potential therapeutic avenue for HCC.

Purpose of the Study:

  • To investigate the therapeutic potential of vitronectin (VTN) inhibition in hepatocellular carcinoma (HCC).
  • To evaluate the effect of VTN silencing on HCC cell growth and tumor development.

Main Methods:

  • RNA interference (RNAi) technology was employed to silence VTN expression in HepG2 and SMMC-7721 HCC cell lines.
  • Cellular growth characteristics were assessed in monolayer and soft agar cultures.
  • Tumor xenograft growth in nude mice was evaluated following VTN silencing.

Main Results:

  • VTN silencing did not impact monolayer cell culture growth but significantly suppressed colony formation in soft agar (over 70% inhibition in HepG2, over 80% in SMMC-7721).
  • VTN silencing led to a 46.6% reduction in tumor xenograft size in nude mice, particularly in males.
  • These findings highlight VTN's role in promoting aggressive tumor behavior.

Conclusions:

  • Vitronectin (VTN) plays a critical role in the malignant progression of hepatocellular carcinoma.
  • Inhibiting VTN demonstrates significant potential as a therapeutic strategy for treating liver cancer.
  • Targeting VTN warrants further investigation for clinical application in HCC therapy.
Keywords:
colony formationhepatocellular carcinomamouse xenograftssiRNAvitronectin

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
The In Ovo Chick Chorioallantoic Membrane CAM Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma08:17

The In Ovo Chick Chorioallantoic Membrane CAM Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma

Published on: October 9, 2015

36.0K

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
55